SK bioscience Co.,Ltd. (KRX:302440)

South Korea · Delayed Price · Currency is KRW

38,600

+1,000 (2.66%)

Jul 7, 2026, 9:55 AM KST

-20.82% (1Y)

Market Cap	2.95T -18.7%
Revenue (ttm)	665.42B +66.4%
Net Income	-83.29B
EPS	-1,062.89
Shares Out	78.46M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,494
Open	36,800
Previous Close	37,600
Day's Range	36,800 - 38,600
52-Week Range	33,850 - 61,300
Beta	0.88
Analysts	Sell
Price Target	33,250.00 (-13.86%)
Earnings Date	Aug 12, 2026

About SK bioscience

SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical tr... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2018

Employees 917

Stock Exchange Korea Stock Exchange

Ticker Symbol 302440

Full Company Profile

Financial Performance

In 2025, SK bioscience's revenue was 651.37 billion, an increase of 143.46% compared to the previous year's 267.55 billion. Losses were -57.42 billion, 6.58% more than in 2024.

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for 302440 stock is "Sell." The 12-month stock price target is ₩33,250, which is a decrease of -13.86% from the latest price.

Price Target

₩33,250

(-13.86% downside)

Analyst Consensus: Sell

Stock Forecasts